Literature DB >> 31612383

Double-edge Role of B Cells in Tumor Immunity: Potential Molecular Mechanism.

Kai-Liang Zhao1, Xiao-Jia Yang1, Hong-Zhong Jin1, Liang Zhao1, Jian-Li Hu2, Wen-Juan Qin3.   

Abstract

B cells are a heterogeneous population, which have distinct functions of antigen presentation, activating T cells, and secreting antibodies, cytokines as well as protease. It is supposed that the balance among these B cells subpopulation (resting B cells, activated B cells, Bregs, and other differentiated B cells) will determine the ultimate role of B cells in tumor immunity. There has been increasing evidence supporting opposite roles of B cells in tumor immunity, though there are no general acceptable phenotypes for them. Recent years, a new designated subset of B cells identified as Bregs has emerged from immunosuppressive and/or regulatory functions in tumor immune responses. Therefore, transferring activated B cells would be possible to become a promising strategy against tumor via conquering the immunosuppressive status of B cells in future. Understanding the potential mechanism of double-edge role of B cells will help researchers utilize activated B cells to improve their anti-tumor response. Moreover, the molecular pathways related to B cell differentiation are involved in its tumor-promoting effect, such as NF-κB, STAT3, BTK. So, we review the molecular and signaling pathway mechanisms of B cells involved in both tumor-promoting and tumor-suppressive immunity, in order to help researchers optimize B cells to fight cancer better.

Entities:  

Keywords:  B cells; tumor immunity

Mesh:

Substances:

Year:  2019        PMID: 31612383     DOI: 10.1007/s11596-019-2092-5

Source DB:  PubMed          Journal:  Curr Med Sci        ISSN: 2523-899X


  47 in total

1.  Hif1a Deletion Reveals Pro-Neoplastic Function of B Cells in Pancreatic Neoplasia.

Authors:  Kyoung Eun Lee; Michelle Spata; Lauren J Bayne; Elizabeth L Buza; Amy C Durham; David Allman; Robert H Vonderheide; M Celeste Simon
Journal:  Cancer Discov       Date:  2015-12-29       Impact factor: 39.397

Review 2.  B cell-derived cytokines in disease.

Authors:  Moustafa Hamze; Caroline Desmetz; Paul Guglielmi
Journal:  Eur Cytokine Netw       Date:  2013-03       Impact factor: 2.737

3.  Inhibitory effects of B cells on antitumor immunity.

Authors:  Satoshi Inoue; Wolfgang W Leitner; Basil Golding; Dorothy Scott
Journal:  Cancer Res       Date:  2006-08-01       Impact factor: 12.701

4.  The absence of B lymphocytes reduces the number and function of T-regulatory cells and enhances the anti-tumor response in a murine tumor model.

Authors:  Tamar Tadmor; Yu Zhang; Hyun-Mi Cho; Eckhard R Podack; Joseph D Rosenblatt
Journal:  Cancer Immunol Immunother       Date:  2011-01-21       Impact factor: 6.968

5.  Adoptive transfer of tumor reactive B cells confers host T-cell immunity and tumor regression.

Authors:  Qiao Li; Xiangming Lao; Qin Pan; Ning Ning; Ji Yet; Yingxin Xu; Shengping Li; Alfred E Chang
Journal:  Clin Cancer Res       Date:  2011-06-20       Impact factor: 12.531

6.  Human B cells express functional TRAIL/Apo-2 ligand after CpG-containing oligodeoxynucleotide stimulation.

Authors:  Troy J Kemp; Jill M Moore; Thomas S Griffith
Journal:  J Immunol       Date:  2004-07-15       Impact factor: 5.422

7.  Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer.

Authors:  Michael D Iglesia; Benjamin G Vincent; Joel S Parker; Katherine A Hoadley; Lisa A Carey; Charles M Perou; Jonathan S Serody
Journal:  Clin Cancer Res       Date:  2014-06-10       Impact factor: 12.531

8.  Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy.

Authors:  Shabnam Shalapour; Joan Font-Burgada; Giuseppe Di Caro; Zhenyu Zhong; Elsa Sanchez-Lopez; Debanjan Dhar; Gerald Willimsky; Massimo Ammirante; Amy Strasner; Donna E Hansel; Christina Jamieson; Christopher J Kane; Tobias Klatte; Peter Birner; Lukas Kenner; Michael Karin
Journal:  Nature       Date:  2015-04-29       Impact factor: 49.962

9.  JSI124 inhibits breast cancer cell growth by suppressing the function of B cells via the downregulation of signal transducer and activator of transcription 3.

Authors:  Yi Ren; Kun Yu; Su'an Sun; Zhi Li; Jin Yuan; Xue Dong Han; Jianhua Shi; Linlin Zhen
Journal:  Oncol Lett       Date:  2014-06-04       Impact factor: 2.967

10.  CD40-activated B cells induce anti-tumor immunity in vivo.

Authors:  Kerstin Wennhold; Tanja M Weber; Nela Klein-Gonzalez; Martin Thelen; Maria Garcia-Marquez; Geothy Chakupurakal; Anne Fiedler; Hans A Schlösser; Rieke Fischer; Sebastian Theurich; Alexander Shimabukuro-Vornhagen; Michael von Bergwelt-Baildon
Journal:  Oncotarget       Date:  2017-04-25
View more
  4 in total

Review 1.  Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don't) know.

Authors:  Simone Camelliti; Valentino Le Noci; Francesca Bianchi; Claudia Moscheni; Francesca Arnaboldi; Nicoletta Gagliano; Andrea Balsari; Marina Chiara Garassino; Elda Tagliabue; Lucia Sfondrini; Michele Sommariva
Journal:  J Exp Clin Cancer Res       Date:  2020-11-09

2.  Analysis of Immune Landscape Reveals Prognostic Significance of Cytotoxic CD4+ T Cells in the Central Region of pMMR CRC.

Authors:  Jingwen Qi; Xiaoyan Liu; Peian Yan; Shangwen He; Yuhao Lin; Zhiwei Huang; Shenyan Zhang; Siyu Xie; Yanfeng Li; Xiaofei Lu; Yingjun Wu; Yangshu Zhou; Juanjuan Yuan; Ting Cai; Xiaojun Zheng; Yanqing Ding; Wei Yang
Journal:  Front Oncol       Date:  2021-09-22       Impact factor: 6.244

Review 3.  Mechanism underlying the immune checkpoint inhibitor-induced hyper-progressive state of cancer.

Authors:  Peng Ding; Lu Wen; Fan Tong; Ruiguang Zhang; Yu Huang; Xiaorong Dong
Journal:  Cancer Drug Resist       Date:  2022-02-08

Review 4.  Tumor-infiltrating B cells as a favorable prognostic biomarker in breast cancer: a systematic review and meta-analysis.

Authors:  You Qin; Fei Peng; Lisha Ai; Shidai Mu; Yuting Li; Chensu Yang; Yu Hu
Journal:  Cancer Cell Int       Date:  2021-06-12       Impact factor: 5.722

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.